Specific Keynote: Immunological Therapy for Ovarian Cancer
- 1 January 2003
- journal article
- review article
- Published by Elsevier in Gynecologic Oncology
- Vol. 88 (1) , S105-S109
- https://doi.org/10.1006/gyno.2002.6695
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Induction of CA125-Specific B and T Cell Responses in Patients Injected with MAb-B43.13—Evidence for Antibody-Mediated Antigen-Processing and Presentation of CA125 in VivoCancer Biotherapy & Radiopharmaceuticals, 2001
- Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2New England Journal of Medicine, 2001
- Intraperitoneal Interferon-α in Residual Ovarian Carcinoma: A Phase II Gynecologic Oncology Group StudyGynecologic Oncology, 1999
- Intraperitoneal α-Interferon Alternating with Cisplatin in Residual Ovarian Carcinoma: A Phase II Gynecologic Oncology Group StudyGynecologic Oncology, 1999
- Immunotherapy of Human Ovarian Carcinoma with OVAREXTM MAb-B43.13 in a Human-PBL-SCID/BG Mouse ModelHybridoma, 1999
- Clinical Course of Ovarian Cancer Patients Under Repeated Stimulation of HAMA Using MAb OC125 and B43.13Hybridoma, 1993
- Intraperitoneal immunotherapy for ovarian cancer with alpha interferonEuropean Journal Of Cancer, 1992
- Anti‐tumor and immunomodulatory activity of intraperitoneal IFN‐γ in ovarian carcinoma patients with minimal residual tumor after chemotherapyInternational Journal of Cancer, 1992
- A phase I–II trial of intraperitoneal cisplatin and α-lnterferon in patients with persistent epithelial ovarian cancerGynecologic Oncology, 1990
- Intraperitoneal human recombinant interferon alpha-2b in minimal residual ovarian cancerEuropean Journal of Cancer and Clinical Oncology, 1990